What the FDA labels say about taking them together
Dextroamphetamine and lisdexamfetamine
Lisdexamfetamine's FDA label of April 30, 2026 names dextroamphetamine in its drug interactions section; dextroamphetamine's label does not name lisdexamfetamine itself but warns about its class (Stimulants). The lisdexamfetamine label: “The co-administration with cytochrome P450 2D6 (CYP2D6) inhibitors may also increase the risk with increased exposure to the active metabolite of ARYNTA (dextroamphetamine).”
Check it at the source: the dextroamphetamine FDA label on DailyMed (effective November 26, 2025, Azurity Pharmaceuticals, Inc.); the lisdexamfetamine FDA label on DailyMed (effective April 30, 2026, Takeda Pharmaceuticals America, Inc.).
What does the dextroamphetamine label say about lisdexamfetamine?
Dextroamphetamine's label does not name lisdexamfetamine itself; it warns about its class (Stimulants):
Dextroamphetamine label, boxed warningMisuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (see OVERDOSAGE ), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Dextroamphetamine label, warningsIf concomitant use of dextroamphetamine sulfate tablets with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate dextroamphetamine sulfate tablets with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. …
Source: FDA drug label (Zenzedi), Azurity Pharmaceuticals, Inc., effective November 26, 2025 (SPL set d6394df5-f2c9-47eb-b57e-f3e9cfd94f84), via openFDA; the full label on DailyMed
What does the lisdexamfetamine label say about dextroamphetamine?
Lisdexamfetamine label, drug interactionsClinical Impact; The concomitant use of VYVANSE and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of VYVANSE compared to the use of the drug alone and increase the risk of serotonin syndrome.
Lisdexamfetamine label, warnings and precautionsThe co-administration with cytochrome P450 2D6 (CYP2D6) inhibitors may also increase the risk with increased exposure to the active metabolite of VYVANSE (dextroamphetamine).
Source: FDA drug label (Arynta, NDA219847), Azurity Pharmaceuticals, Inc., effective July 30, 2025 (SPL set 71cdfc97-96af-4378-a44a-6d5d77e7d6b7), via openFDA
Source: FDA drug label (Vyvanse), Takeda Pharmaceuticals America, Inc., effective April 30, 2026 (SPL set 704e4378-ca83-445c-8b45-3cfa51c1ecad), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dextroamphetamine | Lisdexamfetamine | |
|---|---|---|
| Labeled for | ADHD | ADHD, Binge eating disorder |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.373 per tablet 10 mg tablet | $2.44 per capsule 20 mg capsule |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once